Short-Term Comparison of Switching to Brolucizumab or Faricimab from Aflibercept in Neovascular AMD Patients

• Published in: Medicina (Kaunas, Lithuania) Vol. 60; no. 7; p. 1170
• Main Authors: Kin, Akiko, Mizukami, Takahiro, Ueno, Satoru, Mishima, Soichiro, Shimomura, Yoshikazu
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 19.07.2024
• Subjects: aflibercept; age-related macular degeneration; Aged; Aged, 80 and over; Angiogenesis Inhibitors - administration & dosage; Angiogenesis Inhibitors - therapeutic use; Antibodies, Monoclonal, Humanized - therapeutic use; brolucizumab; faricimab; Female; Humans; intravitreal injection; Intravitreal Injections; Macular Degeneration - complications; Macular Degeneration - drug therapy; Male; Middle Aged; Receptors, Vascular Endothelial Growth Factor - administration & dosage; Receptors, Vascular Endothelial Growth Factor - therapeutic use; Recombinant Fusion Proteins - administration & dosage; Recombinant Fusion Proteins - therapeutic use; switching; Treatment Outcome; Vascular endothelial growth factor; Visual acuity; Visual Acuity - drug effects; Basel Switzerland; United States > US; Switzerland; Japan; switching; aflibercept; vascular endothelial growth factor; brolucizumab; faricimab; intravitreal injection; age-related macular degeneration
• ISSN: 1648-9144; 1010-660X; 1648-9144
• DOI: 10.3390/medicina60071170

: In this study, our objective was to assess and compare the changes in visual and structural outcomes among patients with neovascular age-related macular degeneration (nAMD) who were switched from intravitreal aflibercept (IVA) to either intravitreal brolucizumab (IVBr) or intravitreal faricimab (IVF) injections in a clinical setting. : This observational clinical study included 20 eyes of 20 patients switched to brolucizumab and 15 eyes of 14 patients switched to faricimab from aflibercept in eyes with nAMD. We measured the structural outcome (central macular thickness (CMT)) and the visual outcome (best-corrected visual acuity (BCVA); logMAR) as follows: just before the most recent IVA injection (B0), one month after the most recent IVA injection (B1), just before the first IVBr or IVF injection (A0), one month after (A1) and three months after (A3) the first IVBr or IVF injection. : BCVA showed significant improvement at A1 (0.25 ± 0.34) and at A3 (0.19 ± 0.24) compared to A0 (0.38 ± 0.35) in the IVBr group ( = 0.0156, = 0.0166, respectively). CMT (μm) was significantly thinner at A1 (IVBr: 240.55 ± 51.82, IVF: 234.91 ± 47.29) and at A3 (IVBr: 243.21 ± 76.15, IVF: 250.50 ± 72.61) compared to at A0 (IVBr: 303.55 ± 79.18, IVF: 270.33 ± 77.62) in the IVBr group (A1: = 0.0093, A3: = 0.0026) and in the IVF group (A1: = 0.0161, A3: = 0.0093). There was no significant difference in BCVA and CMT improvement observed between two groups at any time point ( > 0.05 for all). : Switching from aflibercept to either brolucizumab or faricimab has a significant anatomical effect in eyes with nAMD and both treatments appear to be effective short-term treatment options. There is a trend towards greater visual improvements and reductions in CMT with brolucizumab.